Results 1 to 10 of about 102,854 (205)
Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma [PDF]
Case Reports in Oncology, 2019 Approximately 50% of patients with metastatic melanoma harbor an activating BRAF mutation. Tumors with activating mutation BRAF gene proliferate excessively and can be treated with targeted BRAF-inhibitors in combination with MEK inhibitors.
Sara Bjursten +7 more
doaj +3 more sources
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. [PDF]
, 2014 Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors.
Cabrilo, Goran +12 more
core +11 more sources
High frequency of BRAF mutations in primary mucinous ovarian carcinoma of Taiwanese patients
Taiwanese Journal of Obstetrics & Gynecology, 2021 Objective: Considering the clinical evidence of BRAF inhibitors that can treat melanoma patients successfully, we aimed to investigate the status of BRAF mutations of primary mucinous ovarian carcinomas (MOC) in Taiwanese women, and apply the emerging ...
Wan-Ru Chao +4 more
doaj +1 more source
Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
Current Issues in Molecular Biology, 2023 The aim of our study was to evaluate the incidence of KRAS/NRAS and BRAF mutations, analyze molecular patterns, and investigate associations with clinical parameters of these mutations in CRC KRAS/NRAS and BRAF mutations analyzed by next-generation ...
İvo Gökmen +8 more
doaj +1 more source
Clinical Medicine Insights: Oncology, 2023 Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to investigate the rate of the BRAF V600E mutation, the relationships between
Tri Bui Dang Minh +15 more
doaj +1 more source
BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey [PDF]
Türk Patoloji Dergisi, 2018 Objective: BRAF is the most common mutation in melanoma. The most common subtype is BRAF V600E, followed by V600K. Initially, the authors aimed to investigate whether clinicopathological features of melanoma are associated with BRAF mutations.
Nuray CAN +11 more
doaj +1 more source
RNF43 is associated with genomic features and clinical outcome in BRAF mutant colorectal cancer
Frontiers in Oncology, 2023 BackgroundColorectal cancer (CRC) patients with BRAF mutation have very poor prognosis. It is urgent to search for prognostic factors of BRAF mutant CRC. RNF43 is a ENF ubiquitin ligase of Wnt signaling.
Peipei Shang +7 more
doaj +1 more source
CRAF R391W is a melanoma driver oncogene. [PDF]
, 2016 Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known.
Atefi, Mohammad +11 more
core +7 more sources
Diagnostic Pathology, 2017 Background Mounting evidence has shown that KRAS and BRAF are somatic mutations associated with low grade serous carcinoma (LGSC) of the ovary. However, the frequency of KRAS or BRAF mutation was variable in literatures, with a frequency of 16–54% for ...
Yan Xu +8 more
doaj +1 more source
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. [PDF]
, 2015 BackgroundPatients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance.MethodsTumor tissue from ten patients with advanced BRAF mutation-positive melanoma who ...
Cronin, Maureen T +9 more
core +3 more sources